Drugs

argenx SE, a global leader in immunology focused on enhancing the lives of those with severe autoimmune conditions, revealed their commitment to advancing efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing phase 2/3 ALKIVIA trial for adults with […]

Pharmanovia, an international pharmaceutical company specializing in novel and revitalized medicines, has augmented its oncology offerings through a licensing agreement for catumaxomab, aimed at treating malignant ascites. With this arrangement, Pharmanovia gains exclusive rights to introduce catumaxomab, a pioneering bi-specific

Illumina, Inc., a prominent entity in DNA sequencing and array technology, has revealed plans to debut TruSight Oncology 500 v2 (TSO 500 v2), an updated version of its leading cancer research assay aimed at facilitating comprehensive genomic profiling (CGP). The

A group of experts, brought together by the National Institutes of Health (NIH), has determined five pivotal aspects of a brain-originating condition that is now recognized as a major cause of vision impairment in children in the US and other

Tagomics Ltd., known for its groundbreaking work in biomarker discovery and diagnostics, has announced a strategic partnership with Agilent Technologies, a key player in genomic tools, to embark on a co-marketing initiative. This collaboration will enable selected clients to access

Abbott, in the third year marking its substantial Diversity in Clinical Trials campaign, has introduced ‘Advancing Diversity in Clinical Trials,’ a publication offering strategies to enhance diversity within clinical research teams throughout the United States. At the same time, Abbott

Verge Genomics, at the forefront of using artificial intelligence (AI) and human-centric data to revolutionize drug discovery and development, has shared news that Eli Lilly & Company (Lilly) has chosen to move forward with developing treatments targeting two validated drug

Samsung Biologics, a renowned contract development and manufacturing organization (CDMO), has recently forged a series of manufacturing agreements with a pharmaceutical company based in Europe. These newly revealed contracts, valued at over $668 million in total, are set to extend

Merck, recognized as MSD outside the United States and Canada, has announced encouraging topline outcomes from the pivotal phase 3 MK-3475A-D77 study. This investigation is analyzing whether the subcutaneous delivery of pembrolizumab—a renowned anti-PD-1 therapy by Merck, commercially known as

Pfizer Inc. has revealed that the European Commission (EC) has authorized the market release of Hympavzi (marstacimab) for the routine prevention of bleeding episodes in individuals aged 12 and older, who weigh at least 35 kg, with severe hemophilia A